NCT06040905 Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
| NCT ID | NCT06040905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chung Shan Medical University |
| Condition | Mild Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-12-26 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-12-26 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of mild cognitive impairment (MCI). * Clinical diagnosis of Alzheimer's Disease. * MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL). * MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance). * Must be able to swallow tablets. Exclusion Criteria: * Cancer patients. * Severe heart, lung, liver, and kidney diseases. * Severe disability or aphasia. * Malnutrition (body weight changes \> 5% within one month). * Using coenzyme Q10 supplements. * Warfarin therapy.
Contact & Investigator
Ping-Ting Lin, Ph.D.
STUDY DIRECTOR
Chung Shan Medical University
Frequently Asked Questions
Who can join the NCT06040905 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06040905 currently recruiting?
Yes, NCT06040905 is actively recruiting participants. Contact the research team at apt810@csmu.edu.tw for enrollment information.
Where is the NCT06040905 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT06040905 clinical trial?
NCT06040905 is sponsored by Chung Shan Medical University. The principal investigator is Ping-Ting Lin, Ph.D. at Chung Shan Medical University. The trial plans to enroll 100 participants.